Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 12Lymphoma 9Lymphoma, T-Cell 8Mycosis Fungoides 5Lymphoma, T-Cell, Peripheral 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Hematologic Neoplasms 3Urinary Bladder Neoplasms 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Colorectal Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thrombocythemia, Essential 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11Bortezomib 8Filgrastim 7fludarabine 6Vorinostat 6Etoposide 6tanespimycin 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Doxorubicin 5Busulfan 5aldesleukin 4Vincristine 4Tacrolimus 4Paclitaxel 4Lenalidomide 4Gemcitabine 4sargramostim 3nelarabine 3Whole-Body Irradiation 3Topotecan 3Leucovorin 3Irinotecan 3Fluorouracil 3Everolimus 3Dexamethasone 3Dasatinib 3Cytarabine 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × romidepsin × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡